Akums opens new facility for lyophilised and sterile dosage manufacturing

Akums Drugs & Pharmaceuticals Ltd. has opened a new sterile manufacturing facility for lyophilized products, equipped with advanced technology and increased production capacity. This positions the company to meet the growing global demand for these products, with the market expected to reach $4,978.3 million by 2030.